Time to 12-month remission and treatment failure for generalised and unclassified epilepsy

被引:16
作者
Bonnett, Laura J. [1 ]
Smith, Catrin Tudur [1 ]
Smith, David [2 ]
Williamson, Paula R. [1 ]
Chadwick, David [2 ]
Marson, Anthony G. [3 ]
机构
[1] Univ Liverpool, Dept Biostat, Liverpool L9 7LJ, Merseyside, England
[2] Walton Ctr Fdn NHS Trust, Dept Neurol, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L9 7LJ, Merseyside, England
基金
美国国家卫生研究院;
关键词
MULTICENTER COMPARATIVE TRIAL; SODIUM VALPROATE; FRACTIONAL POLYNOMIALS; ANTIEPILEPTIC DRUGS; CARBAMAZEPINE; MODELS; RISK; PHENOBARBITONE; LAMOTRIGINE; PREGNANCY;
D O I
10.1136/jnnp-2013-306040
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To develop prognostic models for time to 12-month remission and time to treatment failure after initiating antiepileptic drug monotherapy for generalised and unclassified epilepsy. Methods We analysed data from the Standard and New Antiepileptic Drug (arm B) study, a randomised trial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or unclassified epilepsy. Multivariable regression modelling was used to investigate how clinical factors affect the probability of achieving 12-month remission and treatment failure. Results Significant factors in the multivariable model for time to 12-month remission were having a relative with epilepsy, neurological insult, total number of tonic-clonic seizures before randomisation, seizure type and treatment. Significant factors in the multivariable model for time to treatment failure were treatment history (antiepileptic drug treatment prior to randomisation), EEG result, seizure type and treatment. Conclusions The models described within this paper can be used to identify patients most likely to achieve 12-month remission and most likely to have treatment failure, aiding individual patient risk stratification and the design and analysis of future epilepsy trials.
引用
收藏
页码:603 / 610
页数:8
相关论文
共 31 条
[11]  
2-4
[12]   PHENOBARBITONE, PHENYTOIN, CARBAMAZEPINE, OR SODIUM VALPROATE FOR NEWLY-DIAGNOSED ADULT EPILEPSY - A RANDOMIZED COMPARATIVE MONOTHERAPY TRIAL [J].
HELLER, AJ ;
CHESTERMAN, P ;
ELWES, RDC ;
CRAWFORD, P ;
CHADWICK, D ;
JOHNSON, AL ;
REYNOLDS, EH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (01) :44-50
[13]  
Hosmer DW., 2000, Applied logistic regression, DOI DOI 10.1002/0471722146.CH4
[14]  
Johnson MR, 2003, TWIN RES, V6, P140, DOI 10.1375/twin.6.2.140
[15]   Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial [J].
Kim, LG ;
Johnson, TL ;
Marson, AG ;
Chadwick, DW .
LANCET NEUROLOGY, 2006, 5 (04) :317-322
[16]   Centring in regression analyses: a strategy to prevent errors in statistical inference [J].
Kraemer, HC ;
Blasey, CM .
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2004, 13 (03) :141-151
[17]  
MacDonald BK, 2000, ANN NEUROL, V48, P833, DOI 10.1002/1531-8249(200012)48:6<833::AID-ANA3>3.3.CO
[18]  
2-L
[19]   Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial [J].
Marson, A ;
Jacoby, A ;
Johnson, A ;
Kim, L ;
Gamble, C ;
Chadwick, D .
LANCET, 2005, 365 (9476) :2007-2013
[20]   The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial [J].
Marson, Anthony G. ;
Al-Kharusi, Asya M. ;
Alwaidh, Muna ;
Appleton, Richard ;
Baker, Gus A. ;
Chadwick, David W. ;
Cramp, Celia ;
Cockerell, Oliver C. ;
Cooper, Paul N. ;
Doughty, Julie ;
Eaton, Barbara ;
Gamble, Carrot ;
Goulding, Peter J. ;
Howell, Stephen J. L. ;
Hughes, Adrian ;
Jackson, Margaret ;
Jacoby, Ann ;
Kellett, Mark ;
Lawson, Geoffrey R. ;
Leach, John Paul ;
Nicolaides, Paola ;
Roberts, Richard ;
Shackley, Phil ;
Shen, Jing ;
Smith, David F. ;
Smith, Philip E. M. ;
Smith, Catrin Tudur ;
Vanoli, Alessandr A. ;
Williamson, Paula R. .
LANCET, 2007, 369 (9566) :1016-1026